UNSPSC 51334405: Cloxypendyl

This classification denotes an antipsychotic agent with the molecular formula C20H25ClN4OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8BK5DLR67A, chemically known as 4-(3-(3-chloro-10h-pyrido(3,2-b)(1,4)benzothiazin-10-yl)propyl)-1-piperazine ethanol but generally known as cloxypendyl, which bears US NIH Compound Identifier 65615. European Medicines Agency schedules Cloxypendyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06786MIG.

UNSPSC 51334405 Cloxypendyl, a Commodity code, describes pharmaceutical products and drug-related systems that state and local governments procure to support public health and safety initiatives. Recent solicitations under this code show state and local buyers purchasing naloxone units and safe drug deactivation systems for community health programs, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements, and exploring direct-to-manufacturer prescription fulfillment models to improve pharmacy benefit program efficiency. The issuing bodies span county health departments, state HHS agencies, and multistate cooperative purchasing alliances, with Seminole County (Florida), the Texas Health and Human Services Commission, and the Minnesota Department of Administration appearing in recent opportunities. Work solicited includes fixed procurement of naloxone and deactivation systems for quarterly delivery, manufacturer-direct generic pharmaceutical supply agreements with specified National Drug Codes and pricing models, and strategic market intelligence gathering on direct contracting capabilities for pharmacy benefit programs.

Recent activity concentrates in the Southeast and Upper Midwest. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: deadline date appears misaligned in source); the contract includes a two-year initial term with one-year renewal option and quarterly delivery requirements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, with proposals due March 26, 2026, to establish multi-vendor contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with contract effectiveness July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in early April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs—a preliminary market-intelligence phase rather than a formal competitive solicitation. Cooperative purchasing vehicles and multistate alliances appear to structure significant pharmaceutical procurement activity at the state and local level.